TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22242967

Group type: EXPERIMENTAL
Intervention: Febuxostat 120 mg daily for 9 days (regimen A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Matching placebo (regimen B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of regimen A to regimen B
Number of subjects: 39
Study: 19464001

Group type: EXPERIMENTAL
Intervention: P(4) + oral E(2) valerate
Number of subjects: 274

Group type: COMPARATOR
Intervention: P(4) only
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: P(4) + hCG
Number of subjects: 274
Study: 17149589

Group type: EXPERIMENTAL
Intervention: 6-week exercise programme (n = 10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 17
Study: 15082189

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no alcohol consumption)
Number of subjects: 0
Study: 11239528

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD
Number of subjects: 11
Study: 9127916

Group type: EXPERIMENTAL
Intervention: Active back rehabilitation program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 41
Study: 7953888

Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Gm‐CSF
Number of subjects: 315

Group type: COMPARATOR
Intervention: G‐CSF and Gm‐CSF
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Hematopoietic factors
Number of subjects: 315
Study: 3310744

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29154814

Group type: EXPERIMENTAL
Intervention: Aquarobic exercise
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aquarobic exercise and burdock intake combination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Burdock intake
Number of subjects: 40
Study: 25878053

Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 1806

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Memory training (active control)
Number of subjects: 1806
Study: 24977154

Group type: EXPERIMENTAL
Intervention: Sharp Turning (ST)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Corner Turning (CT)
Number of subjects: 29
Study: 22394041

Group type: EXPERIMENTAL
Intervention: Self-gripping mesh
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fibrin glue mesh fixation
Number of subjects: 50
Study: 20932805

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 304

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 304
Study: 19127582

Group type: EXPERIMENTAL
Intervention: Nonmotor manifestations of Parkinson's disease
Number of subjects: 0
Study: 15737664

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 14504313

Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin (IVIg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential treatment with PE followed by IVIg or immunoabsorption followed by IVIg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PE and IVIg
Number of subjects: 0
Study: 12695731

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 10220006

Group type: EXPERIMENTAL
Intervention: Dimensional Assessment of Personality Pathology ‐ Basic Questionnaire (DAPP‐BQ)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Cluster membership associated with DSM‐IV diagnosis
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Empirical classification of eating‐disordered patients
Number of subjects: 136
Study: 7529993

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Observation only (Control)
Number of subjects: 112
Study: 2212394

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Corn oil supplementation (n-6 fatty acids)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline measurements (control for other variables)
Number of subjects: 10
Study: 346042

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA) after placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo after MPA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MPA treated patients
Number of subjects: 28
Study: 31399932

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 87
Study: 28146397

Group type: EXPERIMENTAL
Intervention: Interference Screw (IS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Suture Anchor (SA)
Number of subjects: 80
Study: 26288299

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic program
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no psychotherapeutic program)
Number of subjects: 154
Study: 24355450

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (monthly videoconferences with a nurse for 32 weeks)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 165
Study: 22335087

Group type: EXPERIMENTAL
Intervention: Height and weight adjusted dose of intrathecal hyperbaric bupivacaine (Group AD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed dose of intrathecal hyperbaric bupivacaine (2.2 ml) (Group FD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed dose of intrathecal hyperbaric bupivacaine (Group FD)
Number of subjects: 100
Study: 19204412

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 18
Study: 16895948

Group type: EXPERIMENTAL
Intervention: Perioperative hyperinsulinemic normoglycemic clamp (regular insulin at a fixed rate of 0.1 IU.kg(‐1).h(‐1)) during 26 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group receiving standard care
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Perioperative hyperinsulinemic normoglycemic clamp
Number of subjects: 44
Study: 14745701

Group type: EXPERIMENTAL
Intervention: Postexposure prophylaxis (PEP) for 10 days (n=410)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Treatment of ill index cases with oseltamivir for 5 days (n=402)
Number of subjects: 1110
Study: 11355938

Group type: EXPERIMENTAL
Intervention: CA 125 monitoring during first-line chemotherapy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: New assessment criterion based on an increment of 2.5 times the baseline CA 125 concentration
Number of subjects: 255
Study: 9276854

Group type: EXPERIMENTAL
Intervention: Single hop for distance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triple hop for distance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cross-over hop for distance
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6-m timed hop
Number of subjects: 20
Study: 8133020

Group type: EXPERIMENTAL
Intervention: 1 g DGLA
Number of subjects: 66

Group type: COMPARATOR
Intervention: 1 g safflower oil
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dietary sodium intake (70 mmol/day difference)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dietary sodium intake
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Waist: hip ratio
Number of subjects: 66
Study: 3315610

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 87

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 87
Study: 31358034

Group type: COMPARATOR
Intervention: Sham TEAS (Con group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEAS during preoperative and intraoperative periods, sham TEAS postoperative (T1 group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEAS during preoperative, sham TEAS intraoperative, TEAS postoperative (T2 group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEAS before, during, and after operation (T3 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TEAS (Con' group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sham TEAS (T1' group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-Hz TEAS (T2' group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100-Hz TEAS (T3' group)
Number of subjects: 0
Study: 27888086

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 375
Study: 25571933

Group type: EXPERIMENTAL
Intervention: Independent group (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Supervised group (n=12)
Number of subjects: 24
Study: 23347793

Group type: EXPERIMENTAL
Intervention: pegaptanib injection
Number of subjects: 235

Group type: COMPARATOR
Intervention: sham injection
Number of subjects: 235
Study: 21629200

Group type: EXPERIMENTAL
Intervention: Liquid L-carnitine (50 mg L-carnitine/kg bodyweight/day) for 3 months
Number of subjects: 30
Study: 20144362

Group type: EXPERIMENTAL
Intervention: Levemir (insulin detemir) FlexPen
Number of subjects: 61

Group type: COMPARATOR
Intervention: OptiClik (insulin glargine)
Number of subjects: 61
Study: 17723076

Group type: EXPERIMENTAL
Intervention: S-albuterol 5 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nebulized normal saline placebo
Number of subjects: 22
Study: 14998380

Group type: EXPERIMENTAL
Intervention: Formoterol 9-36 microg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Formoterol > or =9 microg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11682440

Group type: EXPERIMENTAL
Intervention: L-NMMA (16 micromol min(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: L-NMMA (64 micromol min(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined COX and NO inhibition
Number of subjects: 32
Study: 9702445

Group type: EXPERIMENTAL
Intervention: Lisinopril (average of 15 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 26
Study: 8081665

Group type: EXPERIMENTAL
Intervention: methylprednisolone (MP) treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study: 2644918

Group type: EXPERIMENTAL
Intervention: Exercise program (details on dosage and duration not specified)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 986289

Group type: EXPERIMENTAL
Intervention: E.C.T. and phenothiazines
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lithium carbonate and phenothiazines
Number of subjects: 2
Study: 31778442

Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine/prilocaine gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine (Oraqix®)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study: 31618241

Group type: EXPERIMENTAL
Intervention: HOT (34±0°C, 28.3±1.9% RH)
Number of subjects: 17

Group type: COMPARATOR
Intervention: CONTROL (23±0.2°C, 35.8±1.2% RH)
Number of subjects: 17
Study: 28814322

Group type: EXPERIMENTAL
Intervention: Delayed-start design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parallel group RCT
Number of subjects: 0
Study: 25259546

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg a.m.
Number of subjects: 1093

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg p.m.
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Lisinopril 40 mg a.m.
Number of subjects: 1093
Study: 23596347

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl wafer
Number of subjects: 11
Study: 22017889

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Conventional open surgical repair
Number of subjects: 277
Study: 18642046

Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection
Number of subjects: 119

Group type: COMPARATOR
Intervention: Biofeedback training
Number of subjects: 119
Study: 15967527

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 12637196

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 600 IU daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11205095

Group type: EXPERIMENTAL
Intervention: SmokEnders (SE group)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Practice as usual (GP group)
Number of subjects: 139
Study: 15102393

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 65
Study: 8239307

Group type: EXPERIMENTAL
Intervention: Cognitive training + phosphatidylserine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive training + pyritinol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Social support
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cognitive training only
Number of subjects: 40
Study: 3544640

Group type: EXPERIMENTAL
Intervention: Aminophylline (4.5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enprofylline (1.5 mg/kg)
Number of subjects: 20
Study: 31249185

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional dental health education (Control)
Number of subjects: 100
Study: 29462733

Group type: EXPERIMENTAL
Intervention: Hypoxic intervention (18% oxygen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (21% oxygen)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (HIG and CG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypoxic intervention (HIG)
Number of subjects: 50
Study: 26797633

Group type: EXPERIMENTAL
Intervention: L-theanine-based nutrient drink
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 23357971

Group type: EXPERIMENTAL
Intervention: Gemcitabine (dose >17,000 mg/m)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Gemcitabine (dose >15,000 mg/m)
Number of subjects: 156
Study: 21782171

Group type: EXPERIMENTAL
Intervention: Structured verbal information with supplementary written information
Number of subjects: 121

Group type: COMPARATOR
Intervention: Structured verbal information
Number of subjects: 121
Study: 20001434

Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg once daily
Number of subjects: 0
Study: 17284745

Group type: EXPERIMENTAL
Intervention: High-folate diet with 369 mug food folate/d and a placebo capsule (Group A)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group B, 92 microg folic acid/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group C, 191 microg folic acid/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group D, 289 microg folic acid/d)
Number of subjects: 72
Study: 14748940

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (500 mg/d)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Low-dose vitamin C (50 mg/d)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 5-year vitamin C supplementation
Number of subjects: 305
Study: 11844007

Group type: EXPERIMENTAL
Intervention: Living will
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Healthcare power of attorney
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Preference for in-home death
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Desire for hospice services
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Support for moral right to end life
Number of subjects: 2853

Group type: EXPERIMENTAL
Intervention: Support for physician-assisted dying
Number of subjects: 2853
Study: 10209562

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at doses of 0.05, 0.10, or 0.20 lU/kg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7933500

Group type: EXPERIMENTAL
Intervention: Inhalation anesthetics (sevoflurane, isoflurane, halothane) with oxygen and nitrous oxide
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Postoperative analgesics (diclofenac, acetaminophen suppositories, intravenous pentazocine)
Number of subjects: 74
Study: 3124046

Group type: EXPERIMENTAL
Intervention: Oral acyclovir daily for one year
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral acyclovir during outbreaks of herpes
Number of subjects: 44
Study: 30007544

Group type: EXPERIMENTAL
Intervention: Tribendimidine plus ivermectin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Tribendimidine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Tribendimidine plus oxantel-pamoate
Number of subjects: 144

Group type: COMPARATOR
Intervention: Albendazole plus oxantel-pamoate
Number of subjects: 144
Study: 27714799

Group type: EXPERIMENTAL
Intervention: Quick links home page
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Simplified data display
Number of subjects: 641

Group type: COMPARATOR
Intervention: Current MPF home page
Number of subjects: 641

Group type: COMPARATOR
Intervention: Current MPF display
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Stand-alone prescription drug plan (PDP)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Medicare Advantage plan with prescription drug coverage (MA-PD)
Number of subjects: 641
Study: 26210808

Group type: EXPERIMENTAL
Intervention: Femoral Access (FA)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Left Radial Access (LRA)
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: Right Radial Access (RRA)
Number of subjects: 1493
Study: 23948440

Group type: EXPERIMENTAL
Intervention: Daily oral multivitamin supplementation (vitamin B complex, C and E) for 24 months
Number of subjects: 2387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2387
Study: 21125461

Group type: EXPERIMENTAL
Intervention: Clazosentan 1 mg/h
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 18708436

Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 43
Study: 18196636

Group type: EXPERIMENTAL
Intervention: Thyroliberin 500 mcg twice a day for 5 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Thyroliberin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 14730113

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg of Zn2+ once daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10705331

Group type: EXPERIMENTAL
Intervention: Local anesthesia (n = 180)
Number of subjects: 400

Group type: COMPARATOR
Intervention: General anesthesia (n = 100)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Spinal anesthesia (n = 100)
Number of subjects: 400
Study: 9334792

Group type: EXPERIMENTAL
Intervention: Written information only
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Guided discussion
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Personalized decision exercise
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Carefully written information
Number of subjects: 248
Study: 1438004

Group type: EXPERIMENTAL
Intervention: Flurbiprofen in the fed state (with water 15 min after 330 ml of apple juice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen in the fasted state (with water)
Number of subjects: 0
Study: 4084483

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromocriptine with prior metoclopramide treatment
Number of subjects: 0
Study: 30811293

Group type: EXPERIMENTAL
Intervention: Bendamustine plus Rituximab (BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP/R-CVP
Number of subjects: 0
Study: 29533491

Group type: EXPERIMENTAL
Intervention: High-dose hemoporfin (5 mg/kg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-dose hemoporfin (2.5 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study: 26523339

Group type: EXPERIMENTAL
Intervention: 3R plus metacomprehension judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JOIs with the 3R strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard 3R
Number of subjects: 0

Group type: COMPARATOR
Intervention: Note-taking plus metacomprehension judgments
Number of subjects: 0
Study: 27501207

Group type: EXPERIMENTAL
Intervention: Acupressure band applied at P6 acupuncture point for 4 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupressure applied with finger pressure at P6 acupuncture point for 4 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group with routine antiemetic therapy only
Number of subjects: 90
Study: 23283457

Group type: COMPARATOR
Intervention: Standard therapy of dapsone and rifampicin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dapsone, rifampicin and clofazimine (U-MDT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: U-MDT
Number of subjects: 40
Study: 20594219

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation plus argon plasma coagulation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Scleroligation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Variceal band ligation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combined endoscopic sclerotherapy and band ligation
Number of subjects: 200
Study: 18341562

Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (2.5 g xylitol, 3 times a day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Xylitol/fluoride lozenges (1.5 mg fluoride, 3 times a day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Reference no-tablet group (n = 70)
Number of subjects: 160